AVGO
Broadcom
-- 216.826 NVDA
NVIDIA
-- 133.270 TSLA
Tesla
-- 426.810 AMD
Advanced Micro Devices
-- 126.170 PLTR
Palantir
-- 73.990 
NEWS
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
Wednesday, 11th December at 8:56 am
• The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.
• The clinical site is led by Brigham and Women's Hospital researchers Ann Woolley, M.D., and David Leaf, M.D.
• The double-blind, placebo-controlled trial will examine outcomes for hospitalized patients with severe babesiosis, a tick-borne illness often found as a co-infection of Lyme disease.
Wednesday, 11th December at 8:56 am
• The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.
• The clinical site is led by Brigham and Women's Hospital researchers Ann Woolley, M.D., and David Leaf, M.D.
• The double-blind, placebo-controlled trial will examine outcomes for hospitalized patients with severe babesiosis, a tick-borne illness often found as a co-infection of Lyme disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment